van Veen Wim, Mali Willem P Th M
Gezondheidsraad, Den Haag, The Netherlands.
Ned Tijdschr Geneeskd. 2009;153:A1441.
There is sufficient evidence that a colorectal cancer (CRC) screening programme is feasible, acceptable and cost-effective amongst the Dutch population. This is the conclusion of the Health Council of the Netherlands in an advisory report to the Minister of Health, Welfare and Sport. It also concluded that an immunochemical faecal occult blood test (iFOBT) would be the obvious screening method. The recommended target group is men and women aged 55-75. An evaluation of the randomized pilot trials in the regions of Nijmegen, Amsterdam, and Rotterdam predicted a participation rate of 60%. Based on the analyses from a microsimulation model, biennial screening for CRC with iFOBT and an uptake rate of 60% could prevent 1400 deaths from CRC per annum, at a cost of 2200 euros per years of life saved.
有充分证据表明，在荷兰人群中开展结直肠癌（CRC）筛查项目是可行的、可接受的且具有成本效益。这是荷兰健康委员会在给卫生、福利和体育部部长的一份咨询报告中得出的结论。报告还得出结论，免疫化学粪便潜血试验（iFOBT）将是理想的筛查方法。推荐的目标群体是55至75岁的男性和女性。对奈梅亨、阿姆斯特丹和鹿特丹地区随机试点试验的评估预测参与率为60%。基于微观模拟模型的分析，采用iFOBT每两年进行一次CRC筛查且接受率为60%，每年可预防1400例CRC死亡，每挽救一年生命的成本为2200欧元。
